Please login to the form below

Not currently logged in
Email:
Password:

Neon Therapeutics taps Dr Richard Gaynor for R&D leadership role

He recently retired from Lilly after more than 15 years with the firm

Neon Therapeutics Richard GaynorNeon Therapeutics has appointed Dr Richard Gaynor as president of research and development to succeed its interim chief scientific office Robert Tepper, who will continue to sit on the firm's board.

Dr Gaynor recently retired from Lilly's oncology division, where he was spent more than 15 years, most recently as senior vice president of global product development and medical affairs.

At Cambridge, US-based Neon he will be tasked with guiding the immuno-oncology company's research programmes, which are focused on developing neoantigen-based therapeutic vaccines and T cell therapies.

Hugh O'Dowd, chief executive officer of Neon Therapeutics said the company was privileged to have Dr Gaynor join its team.

“Richard brings an enormous depth of oncology experience, having overseen many innovative drugs through early research into clinical development and commercialisation. His knowledge and leadership reinforces Neon Therapeutics' leadership in neoantigen-based immuno-oncology treatments.”

Dr Gaynor began his career in academia before joining Lilly in 2002 to oversee both oncology drug discovery and early clinical development.

12th December 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...